peptide1

General Information


DRACP ID  DRACP01597

Peptide Name   peptide1

Sequence  FLSGIVGMLGKLF

Sequence Length  13

UniProt ID  B3KYH4 

PubChem CID  Not available

Origin  analogs of antimicrobial peptide temporin-SHa

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
MCF-7 Invasive breast carcinoma of no special type Carcinoma IC50=14.47 ± 0.57 μM MTT assay 24 h Patent
HeLa Human papillomavirus-related endocervical adenocarcinoma Carcinoma IC50=18.36 ± 0.92 μM MTT assay 24 h Patent
NCI-H460 Lung large cell carcinoma Carcinoma IC50=34.49 ± 1.5 μM MTT assay 24 h Patent

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  NIH 3T3: IC50=73.3 ± 0.08 μM

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01597

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C67H108N14O15S

Absent amino acids  ACDEHNPQRTWY

Common amino acids  GL

Mass  159597

Pl  9.7

Basic residues  1

Acidic residues  0

Hydrophobic residues  7

Net charge  1

Boman Index  2590

Hydrophobicity  166.92

Aliphatic Index  142.31

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  4

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US10550155B2

Patent Title  Anticancer peptides

Other Iinformation  Granted Patent; Family: 2s / 2ex; Family Jurisdictions: US; Legal Status: Active; Application No: 201815937281; Filed: Mar 27, 2018; Published: Feb 4, 2020; Earliest Priority: Mar 27, 2018; Granted: Feb 4, 2020

Other Published ID  US10550155B2 




DRACP is developed by Dr.Zheng's team.